Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks

BACKGROUND: Crenezumab is a fully humanized, monoclonal anti-amyloid-β immunoglobulin G4 antibody. OBJECTIVE: This Phase Ib study (NCT02353598) evaluated the safety, tolerability, and pharmacokinetics of crenezumabat doses of ≤120 mg/kg administered intravenously every 4 weeks (q4w). Immunogenicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Guthrie, Heather, Honig, Lawrence S., Lin, Helen, Sink, Kaycee M., Blondeau, Kathleen, Quartino, Angelica, Dolton, Michael, Carrasco-Triguero, Montserrat, Lian, Qinshu, Bittner, Tobias, Clayton, David, Smith, Jillian, Ostrowitzki, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505005/
https://www.ncbi.nlm.nih.gov/pubmed/32568196
http://dx.doi.org/10.3233/JAD-200134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505005/
https://www.ncbi.nlm.nih.gov/pubmed/32568196
http://dx.doi.org/10.3233/JAD-200134

Ejemplares similares